Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPA | P38571 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6410197 | 0.90 | — | — | |
| SCHEMBL12224296 | 0.90 | LIPA (0.32) | LIPA | |
| SCHEMBL5615220 | 0.83 | EPHX1 (0.42) | LIPAEPHX1GLAEPHX2HSD11B1 | |
| SCHEMBL5270433 | 0.83 | — | — | |
| SCHEMBL22797 | 0.83 | — | — | |
| SCHEMBL11935725 | 0.81 | LIPA (0.42) | LIPAEPHX1GLAEPHX2HSD11B1 | |
| SCHEMBL26153215 | 0.81 | LIPA (0.42) | LIPAEPHX1GLAEPHX2HSD11B1 | |
| SCHEMBL21859777 | 0.81 | LIPA (0.42) | LIPAEPHX1GLAEPHX2HSD11B1 | |
| SCHEMBL26325776 | 0.81 | LIPA (0.42) | LIPAEPHX1GLAEPHX2HSD11B1 | |
| SCHEMBL23570077 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295170-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | LIPA 1436/4885EPHX1 3742/4885GLA 2130/4885 |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | LIPA 2577/4885EPHX1 479/4885GLA 1319/4885 |
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | LIPA 2577/4885EPHX1 479/4885GLA 1319/4885 |
| US-20230174538-A1 | Tricyclic heterocycles | YAP1, TEAD1, TERF2IP | LIPA 4633/4885EPHX1 3709/4885GLA 2323/4885 |
| US-20230295170-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | LIPA 2577/4885EPHX1 479/4885GLA 1319/4885 |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM5 | LIPA 3117/4885EPHX1 889/4885GLA 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.